Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
Chang Zhao(The People's Hospital of Guangxi Zhuang Autonomous Region), Yilong Ma, Bingqiang Ni(The People's Hospital of Guangxi Zhuang Autonomous Region), Zhiyong Zheng(State Administration of Traditional Chinese Medicine of the People's Republic of China), Liwei Fan(The People's Hospital of Guangxi Zhuang Autonomous Region), Qi Feng(Central University of Finance and Economics), Shengqiu Ou(The People's Hospital of Guangxi Zhuang Autonomous Region), Lin Cheng(Qingdao University), Changsheng Chen(The People's Hospital of Guangxi Zhuang Autonomous Region), Xiong Lü(The People's Hospital of Guangxi Zhuang Autonomous Region), Chengwen Zhang(The People's Hospital of Guangxi Zhuang Autonomous Region), Tianlian Hu(The People's Hospital of Guangxi Zhuang Autonomous Region), Lei Yu(Taiyuan Central Hospital), Jianxun Lu(The People's Hospital of Guangxi Zhuang Autonomous Region), Xiaoyu Yi(Capital Institute of Pediatrics)
Cited by 23
Related Papers
Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma
|Journal of Clinical Oncology|2011|644
Chinese expert consensus on the perinatal and neonatal management for the prevention and control of the 2019 novel coronavirus infection (First edition)
|Annals of Translational Medicine|2020|357
Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study
|Clinical Cancer Research|2018|355